GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Up 26.0% in March

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a large growth in short interest in March. As of March 13th, there was short interest totaling 265,418 shares, a growth of 26.0% from the February 26th total of 210,698 shares. Based on an average trading volume of 69,667 shares, the days-to-cover ratio is presently 3.8 days. Currently, 14.6% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research note on Thursday, February 19th. Wall Street Zen cut GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, GeoVax Labs currently has an average rating of “Hold” and a consensus price target of $187.50.

GeoVax Labs Trading Up 1.5%

Shares of GeoVax Labs stock traded up $0.02 during trading on Tuesday, reaching $1.38. The company’s stock had a trading volume of 31,328 shares, compared to its average volume of 139,358. The company has a 50-day moving average price of $2.03 and a two-hundred day moving average price of $7.76. GeoVax Labs has a fifty-two week low of $1.26 and a fifty-two week high of $34.75. The firm has a market cap of $2.51 million, a PE ratio of -0.04 and a beta of 3.82.

Hedge Funds Weigh In On GeoVax Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in GeoVax Labs in the 4th quarter valued at about $99,000. HRT Financial LP purchased a new position in shares of GeoVax Labs in the 4th quarter valued at approximately $31,000. Renaissance Technologies LLC purchased a new position in shares of GeoVax Labs in the 4th quarter valued at approximately $104,000. Hudson Bay Capital Management LP acquired a new position in shares of GeoVax Labs in the third quarter valued at approximately $47,000. Finally, Armistice Capital LLC purchased a new stake in shares of GeoVax Labs during the third quarter worth approximately $253,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.